Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes - Wikidata - wikimedia - TriplyDB

Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes

Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes

http://www.wikidata.org/entity/Q34480377

about

Vaccination against respiratory Pseudomonas aeruginosa infection Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response Integrated whole-genome screening for Pseudomonas aeruginosa virulence genes using multiple disease models reveals that pathogenicity is host specific.Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study The Cyclic AMP-Vfr Signaling Pathway in Pseudomonas aeruginosa Is Inhibited by Cyclic Di-GMP Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.The Dynamics of Disease Progression in Cystic Fibrosis.Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.Cystic fibrosis-adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses.Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Modulation of behaviour and virulence of a high alginate expressing Pseudomonas aeruginosa strain from cystic fibrosis by oral commensal bacterium Streptococcus anginosus.Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus.Use of a Multiplex Transcript Method for Analysis of Pseudomonas aeruginosa Gene Expression Profiles in the Cystic Fibrosis Lung Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa.Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa.Cystic Fibrosis: Microbiology and Host Response Pyomelanin-producing Pseudomonas aeruginosa selected during chronic infections have a large chromosomal deletion which confers resistance to pyocins.Impact of the Respiratory Microbiome on Host Responses to Respiratory Viral Infection.Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.in Chronic Lung Infections: How to Adapt Within the Host?

P2860

Q26824014-EDE7A05E-79C0-444D-931F-1AF869CB9B27 Q30278439-6CF1170A-9FA9-416A-90C4-843D222EA58E Q35358667-5F6079B9-AC77-46C8-9CFA-94FE871FCEF3 Q35595533-C08EE3BA-C52B-417C-B331-05D08B8C2159 Q35607468-BDF0D47D-BC9C-476A-97CB-2F0FAEB83E6C Q35682375-49982C3E-950B-4DD0-8B45-746F69E6B3D1 Q35686899-8B8BF6D6-76EF-4530-A349-BE1B12035E84 Q36036190-42F46927-85DF-45D5-B887-27FF383115BD Q36050609-F3DF13DC-A946-4C69-A2C4-FCAB6F16627D Q36135733-C2FB9CED-5B53-48A7-9E1F-96E964D5D1F5 Q36226940-A2C4C211-66C1-44F8-9282-36F615A78AE6 Q36310773-CA57610C-0FEB-4E4C-B577-3F5FA2D47B6D Q36644742-06F85CFE-E266-4B7A-9974-419BA9CE13BF Q37287175-87062B4A-8B8A-4EF8-8CFE-46459A4EEE6A Q37287759-F0B7D9C8-5D88-4C3F-AA76-0316D17CAC37 Q37310362-BA738B28-ACC4-4925-BE67-43B513C6E11B Q38784356-E1EF3B35-7B05-4099-9401-DE7647E088F1 Q38911644-53AFBD1D-2F38-4F48-86A3-00AC8008B378 Q40696824-D10A064C-0B96-484E-A7EC-B98982FCFD72 Q47158825-6F2DC4C0-CB86-4615-91FB-D4B63E7321A6 Q47720458-4975690A-5D26-4DC3-9DB3-F106F1518F2D Q47730320-BB021603-8403-496D-8E0D-15B0678318BC Q52448914-E2494F68-F1BB-4DFC-B7A6-2193C6B29AB7 Q58580408-8D96A4C2-A046-4E96-AEA9-DB39C0A11250

P2860

Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes

http://www.wikidata.org/entity/Q34480377

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@ast

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@en

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@nl

type

label

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@ast

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@en

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@nl

prefLabel

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@ast

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@en

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@nl

P1433

Q34480377-92D3114D-5105-4B09-8A5A-D55CECE8B47D

P1476

Q34480377-9E425C1C-B90A-41CC-8BCF-CB4B4FEFF623

P2093

Q34480377-160623D4-EE57-4DF8-AD49-0CB7EBC4892E

Q34480377-2661EBB8-E9FF-4D3E-A661-91C468851A08

Q34480377-421C4E79-CA5B-4591-8D3C-5DC69631E62E

Q34480377-44B21A44-C3B6-470C-B259-4FCA056D0692

Q34480377-61EC6188-90BD-40BD-9B00-857E9A18BB25

Q34480377-8279624F-1248-4502-8D99-91B6BD5A460C

Q34480377-874B02D8-62F2-4329-9137-04B43E8C73A4

Q34480377-A61C6B09-49CB-4FD3-A870-7AE0A9E80EA4

Q34480377-C0C12E99-D5BC-4351-AD9A-EE504C1E62F3

Q34480377-C230C1AD-7B5D-40EA-805A-44DD8C0ADDCF

P2860

Q34480377-03041185-362A-49BB-BA8E-7EDAC1E1F878

Q34480377-0869E8F5-CA95-460D-B810-128A8DE643EE

Q34480377-09398879-B7BE-48E3-AF73-029679B5CFFD

Q34480377-1497DA34-4588-43D6-99AE-EADE064538BF

Q34480377-172829E7-2F43-40C6-9C7A-8B6BE4025A10

Q34480377-21D5C6B2-1D23-4226-8CDD-5FE4416B0EDD

Q34480377-2C2155A5-0304-43FC-AE59-45E575180F1C

Q34480377-2C7880F6-D836-4B66-B399-87AE76FD56A2

Q34480377-386D61D3-1025-4382-BAF3-CDE0FA095C6C

Q34480377-40BFC9B6-DE86-4B93-8A29-877549CE8BE9

P304

Q34480377-3564401A-110B-4342-A769-F10DE4154029

P31

Q34480377-16DFAAB7-4283-422B-A7D8-A349F7979DAA

P356

Q34480377-6A7DA6D8-FB85-480A-AD59-44203E2EEC76

P407

Q34480377-40ED3081-F5FD-43FF-AB72-BD1122521E2E

P433

Q34480377-CCE75333-1608-4631-B25E-E43311D84C8C

P478

Q34480377-A3877991-0991-4C5E-9C2E-E60EEF8AAF60

P50

Q34480377-E0B02CAC-8884-4883-B91E-DD0665D09D2E

P577

Q34480377-BE9F044C-507E-4291-94A8-C00B92F13F98

P698

Q34480377-22633D2E-CAF1-43DF-9E22-450B248A5185

P921

Q34480377-4D6D01D0-F927-4EDD-BFEF-B0D8E7961D5D

Q34480377-9215544D-182C-47B6-8BD0-B3CAEAD6742B

P932

Q34480377-2F73BB8D-E2EB-497A-B5BB-75ABE477A060

P356

RCCM.201404-0681OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Pseudomonas aeruginosa in vitr ...... infection stages and outcomes

@en

P2093

Bonnie W Ramsey

http://www.w3.org/2001/XMLSchema#string

Bridget R Kulasekara

http://www.w3.org/2001/XMLSchema#string

Christopher E Pope

http://www.w3.org/2001/XMLSchema#string

Daniel J Wolter

http://www.w3.org/2001/XMLSchema#string

George Z Retsch-Bogart

http://www.w3.org/2001/XMLSchema#string

Hemantha D Kulasekara

http://www.w3.org/2001/XMLSchema#string

Jane L Burns

http://www.w3.org/2001/XMLSchema#string

Laura S Houston

http://www.w3.org/2001/XMLSchema#string

Lucas R Hoffman

http://www.w3.org/2001/XMLSchema#string

Margaret Rosenfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Cystic fibrosis

Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study

Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'

Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.

Predictive 5-year survivorship model of cystic fibrosis.

Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection

Clinical significance of microbial infection and adaptation in cystic fibrosis.

P304

289-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201404-0681OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24937177

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

4226041

http://www.w3.org/2001/XMLSchema#string